17 results on '"Mistry, Arun"'
Search Results
2. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
3. Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg
4. Long-Term Cardiovascular Safety of Fenfluramine HCl in the Treatment of Dravet Syndrome: Interim Analysis of an Open-Label Safety Extension Study
5. Effect of ZX008 (Fenfluramine HCl Oral Solution) on Total Seizures in Dravet Syndrome
6. Fenfluramine HCl Provides Long-Term Clinically Meaningful Reduction in Seizure Frequency: Results of an Open-Label Extension Study
7. Less Convulsive Seizures by Fenfluramin Medication in Stiripentol Treated Patients with Dravet's Syndrome: Results from Randomized, Placebo-controlled Phase 3 Clinical Trial
8. Determinación de la epidemiología, el flujo de pacientes y el tratamiento del síndrome de Dravet en España
9. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
10. IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
11. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome
12. Cultural relevance of the global impact of Dravet Syndrome in Australia, Italy, the US and UK
13. Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures.
14. Less Convulsive Seizures by Fenfluramin Medication in Stiripentol Treated Patients with Dravet's Syndrome: Results from Randomized, Placebo-controlled Phase 3 Clinical Trial.
15. Corrigendum to: “Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg” [Eur Urol 2007;52:1195–1203]
16. Corrigendum to: “Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5mg and Tolterodine ER 4 mg” [Eur Urol 2007;52:1195–1203]
17. Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.